ONTY

Current-4 months: Two compounds, PX-478 and PX-866, have promising preclinical profiles and are both in Phase I trials, with data readouts in '09. Limited number of outstanding shares and small market cap + positive data could warrant a share price increase above their 52 week high of $7.77.

Sentiment: Buy @ $5.30; Strong buy @$5.05

PJP